Personalising therapy for early-stage oestrogen receptor-positive breast cancer in older women

The Lancet Healthy Longevity ◽

10.1016/s2666-7568(21)00280-4 ◽

2022 ◽

Vol 3 (1) ◽

pp. e54-e66

Author(s):

Neil Carleton ◽

Azadeh Nasrazadani ◽

Kristine Gade ◽

Sushil Beriwal ◽

Parul N Barry ◽

...

Keyword(s):

Breast Cancer ◽

Older Women ◽

Oestrogen Receptor ◽

Early Stage ◽

Positive Breast Cancer

Download Full-text

Outcomes After Sentinel Lymph Node Biopsy and Radiotherapy in Older Women With Early-Stage, Estrogen Receptor–Positive Breast Cancer

JAMA Network Open ◽

10.1001/jamanetworkopen.2021.6322 ◽

2021 ◽

Vol 4 (4) ◽

pp. e216322

Author(s):

Neil Carleton ◽

Jian Zou ◽

Yusi Fang ◽

Stephen E. Koscumb ◽

Osama Shiraz Shah ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Sentinel Lymph Node ◽

Older Women ◽

Early Stage ◽

Lymph Node Biopsy ◽

Node Biopsy ◽

Estrogen Receptor Positive ◽

Positive Breast Cancer

Download Full-text

Adoption Patterns and Predictors of De-escalated Adjuvant Therapy for Older Women With Early Stage Hormone Receptor Positive Breast Cancer

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2017.06.1612 ◽

2017 ◽

Vol 99 (2) ◽

pp. E422

Author(s):

T.M. Zagar ◽

C. Baggett ◽

S. Wheeler ◽

X. Zhou ◽

A.M. Meyer ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Therapy ◽

Older Women ◽

Hormone Receptor ◽

Early Stage ◽

Hormone Receptor Positive ◽

Positive Breast Cancer

Download Full-text

Primary endocrine treatment for older women with early-stage hormone receptor-positive breast cancer. Real-World experience from a single UK cancer centre

European Journal of Cancer ◽

10.1016/s0959-8049(20)30816-9 ◽

2020 ◽

Vol 138 ◽

pp. S105

Author(s):

C. Rapti ◽

S. Benafif ◽

C. Nattress ◽

M. Akay ◽

E. Papadimitraki

Keyword(s):

Breast Cancer ◽

Older Women ◽

Hormone Receptor ◽

Early Stage ◽

Endocrine Treatment ◽

Cancer Centre ◽

Hormone Receptor Positive ◽

Positive Breast Cancer

Download Full-text

A phase III trial to determine the activity and safety of fulvestrant (Faslodex®) in premenopausal women with oestrogen-receptor positive breast cancer

European Journal of Cancer ◽

10.1016/s0959-8049(02)80305-7 ◽

2002 ◽

Vol 38 (11) ◽

pp. S97 ◽

Author(s):

J Robertson

Keyword(s):

Breast Cancer ◽

Oestrogen Receptor ◽

Premenopausal Women ◽

Phase Iii ◽

Phase Iii Trial ◽

Positive Breast Cancer

Download Full-text

FDA approves neratinib for extended adjuvant treatment of early stage HER2-positive breast cancer

Case Medical Research ◽

10.31525/fda1-ucm567259.htm ◽

2017 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Adjuvant Treatment ◽

Early Stage ◽

Her2 Positive ◽

Her2 Positive Breast Cancer ◽

Positive Breast Cancer

Download Full-text

Faculty Opinions recommendation of Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717969433.793480577 ◽

2013 ◽

Author(s):

Nancy Lin ◽

Ines Vaz-Luis

Keyword(s):

Breast Cancer ◽

Early Stage ◽

Her2 Positive ◽

Phase 3 ◽

Her2 Positive Breast Cancer ◽

Randomised Controlled ◽

Positive Breast Cancer

Download Full-text

Faculty Opinions recommendation of Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717969556.793525549 ◽

2016 ◽

Author(s):

Daniel Vorobiof

Keyword(s):

Breast Cancer ◽

Oestrogen Receptor ◽

Randomised Trial ◽

Adjuvant Tamoxifen ◽

Long Term Effects ◽

Positive Breast Cancer

Download Full-text

Faculty Opinions recommendation of Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717969556.793480576 ◽

2013 ◽

Author(s):

Nancy Lin ◽

Ines Vaz-Luis

Keyword(s):

Breast Cancer ◽

Oestrogen Receptor ◽

Randomised Trial ◽

Adjuvant Tamoxifen ◽

Long Term Effects ◽

Positive Breast Cancer

Download Full-text

WORSENING BLOOD PRESSURE CONTROL IS ASSOCIATED WITH DECREASED CARDIAC MECHANICS IN EARLY STAGE HER2 POSITIVE BREAST CANCER PATIENTS

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(21)04678-7 ◽

2021 ◽

Vol 77 (18) ◽

pp. 3324

Author(s):

Kimberly Y. Chow ◽

Fei Fei Gong ◽

Nikita Patel ◽

Haydee Ramirez ◽

Milica Marion ◽

...

Keyword(s):

Breast Cancer ◽

Blood Pressure ◽

Cancer Patients ◽

Blood Pressure Control ◽

Early Stage ◽

Cardiac Mechanics ◽

Pressure Control ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Positive Breast Cancer

Download Full-text

E14. The prognostic and predictive value of the progesterone receptor in women with an oestrogen receptor-positive breast cancer

European Journal of Cancer Supplements ◽

10.1016/j.ejcsup.2004.08.013 ◽

2004 ◽

Vol 2 (9) ◽

pp. 46-48 ◽

Keyword(s):

Breast Cancer ◽

Progesterone Receptor ◽

Predictive Value ◽

Oestrogen Receptor ◽

Positive Breast Cancer

Download Full-text